The 315 square meter facility will house more than 30 employees in Warsaw, Poland, where the company contract research organization (CRO) has operated since 2008.
iCardiac Technologies and SNBL CPC Japan, a Japanese-based Site Management Organization (SMO), will collaborate on cardiac safety studies in the country.
Hikma invested over $25m in its US facilities in the first half 2016, and plans to use excess capacity at a former Boehringer Ingelheim plant for contract manufacturing.
Marken’s Moscow-based depot has been granted a new pharmaceutical license from the Russian Federation, further extending the company’s capabilities in the area.
GSK will pump £275m ($360m) into its UK manufacturing network and says the country has a “leading position in life sciences” despite the recent Brexit vote.
Brexit: Indian firms worried but Big Pharma and EMA remain positive for now
ClinTec International has opened two new offices in Spain as it prepares for an expanding local clinical trial portfolio and larger outsourcing engagements in the country.
Anti-LGBT legislation has prompted Braeburn Pharmaceuticals to reassess plans for a $20m facility in North Carolina, but will others in "the nation’s number one state for biomanufacturing" follow suit?
Recipharm will invest €40 in serialization equipment to ensure it can comply with evolving track and trace regulations in the US, Europe and other markets.
AstraZeneca has reformulated roxadustat using materials sourced in China to make it eligible for fast track review through the country's new "green pass" process.
Indian drugmaker Strides Shasun has bolstered its generics manufacturing network by acquiring stakes in Kenya’s Universal Corporation and Australia’s Generic Partners Holdings.
Incoming Indonesian government measures to attract foreign manufacturing joint ventures (JVs) could include a regulation to reduce API imports, Vincent Harijanto, committee head GP Farmasia said.
Ipca has received an FDA Warning Letter at three Indian API facilities, but says it awaits re-inspection after already rectifying issues highlighted in a 2014 Form 483.
Plans to centralise its manufacturing operations will optimise use of new technologies across Novartis’s divisions without resulting in any additional facility closures, the firm says.
More plants in China will close says a US-based analyst who predicts that some drugmakers' inability to comply with stricter quality rules will create an opportunity for those that can.
The recent tide of Warning Letters issued to Chinese API and finished formulation makers reflects an increase in regulatory oversight, the US FDA says.
India’s CRO industry is playing catch-up to the generic and manufacturing sectors, according to the departing CEO of one of the largest players, Syngene.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing waves goodbye to Martin Shkreli… welcome to a New Year’s CEO special.
Niche technologies will differentiate CMOs looking for a slice of the steady oral dosage manufacturing industry, according to an industry report from ISR.
The $160bn Pfizer-Allergan megamerger could lead to booking cancellations in the short-term say analysts, but CROs – especially Icon, Parexel and PPD - should ultimately benefit.
As World Antibiotics Awareness Week draws attention to the threat of resistance, pharma companies large and small say a worldwide overhaul of payment models will make anti-infective R&D profitable again.
The fight between CROs for clinical research associates (CRAs) and people with certain other skillsets is hotting up, with both Icon and Quintiles identifying it as an issue faced by their businesses.
The number of clinical trials given the green light in Russia has increased 13% in the third quarter of the year, which could be thanks in part to a reduction in red tape.
